Email: [email protected]
Pune, January 9,2020
Premium Market Insights has announced the addition of the “Epigenetics Market ”. The report focuses on global major leading industry players with information such as company profiles, product picture and specification.
The Epigenetics market is driven by the driving factor such as declining prices of sequencing, and is likely to drive the market in the coming years. The declining costs associated with different strategies and methods for sequencing supports to influence the scale and scope of almost all genomic research projects. In 2000, cost for sequencing was US$ 3.7 billion, which dropped down to US$ 10 million in 2006 and declined to US$ 5,000 in 2012. Owing to factors such as advances in the field of genomics, development in different methods and strategies for sequencing, there is a notable decline in the cost of sequencing, that upsurge the growth of the market.The market is likely to restrain its growth due to the factors such as high cost of advanced technologies. Companies such as Illumina and PacBio offer instruments with high cost. For instance, Illumina MiSeq cost for US$ 128,000 and PacBio RS cost for US$ 695,000. Thus, the high cost of next generation sequencers is hindering the growth of the market for in the future. Whereas the use of the neuroepigenetics to diagnose the neurodevelopmental disorders is likely to contribute a potential market growth in the forecast period.
The Epigenetics market as per the product the segment is segmented as reagents, kits, enzymes, instruments and consumables and bioinformatics tools. The market of kits has the highest market share in 2017, contributing a market share of 29.8% and is expected to retain its dominance during the forecast period from 2018 to 2025. The epigenetic kits allows researchers to perform experiments, researchers to analyze epigenetic modifications efficiently and reliably by using antibodies directed against epitope tags or RNA-binding proteins. Thus holding the major market share. Likewise the reagents contributed 26.2% of the market share in the year 2017 and is expected to be the fastest growing market in the coming near future.
Get Sample PDF For More Professional And Technical Insights at:
The Technology segment of the epigenetics market includes histone modification, DNA methylation and other technologies. The DNA methylation segment for the epigenetics market was valued at US$ 506.29 Mn in 2017 and is estimated to grow at a CAGR of 13.9% during the forecast period from 2017 to 2025, to reach US$ 1,361.67.0 Mn by 2025. The DNA methylation segments is likely to dominate the market in the coming future as it supports the development of therapies for diseases including cancer, lupus, muscular dystrophy and various congenital defects. Thus the DNA methylation segment is expected to hold major share and is also the fastest growing segment during the forecast period.
Some of the major primary and secondary sources included in the report epigenetics market are National Institute of Environmental Health Sciences (NIEHS), Epidemiology and Genomics Research Program (EGRP), Canadian Institutes of Health Research (CIHR), Synthetic Biology Leadership Council, Chinese Academy of Sciences, World Health Organization, European Union, Food and Drug Administration and more.
Get Complete Report at: https://www.premiummarketinsights.com/reports-tip/epigenetics-market
Name: Sameer Joshi
Email: [email protected]
Organization: Premium Market Insights
About Premium Market Insights:
Premium Market Insights is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries. Our commitment to customer service is best exemplified by free analyst support that we offer to our clients which sets us apart from any other provider.